A new publication on difelikefalin was released on September 23, 2026. The study, titled "Efficacy and Safety of Switching from Nalfurafine to Difelikefalin in Hemodialysis Patients with Refractory Pruritus," appeared in the Journal of Personalized Medicine.
The publication focuses on hemodialysis patients with refractory pruritus who were switched from nalfurafine to difelikefalin. It was indexed under PubMed ID 42930764.
Difelikefalin is an approved compound. This entry reflects the release of a new peer reviewed publication and does not describe specific findings beyond the study title and subject matter provided here.
Readers interested in more background can consult the compound overview for additional context on difelikefalin.